Reportable segments
Reportable segments: CAG, Water, and LPD; Other reconciling
Source evidence
“We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations”

IDXX
Updated: 04/11/2026, 10:31:10
No historical data available
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
No summaries found.
Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.
Revenue
$4.3B
FY 2025 · Reported
Net income
$1.1B
FY 2025 · Reported
Gross margin
61.8%
FY 2025 · Calculated
Free cash flow
$1.1B
FY 2025 · Calculated
R&D intensity
5.8%
FY 2025 · Calculated
Share repurchases
$1.2B
FY 2025 · Reported
Other offerings mentioned without separate sales
Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.
Map layer
Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.
Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.
Reportable segments
Reportable segments: CAG, Water, and LPD; Other reconciling
“We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations”
CAG revenue by product/service line FY2025
CAG Diagnostics recurring $3,407.2M (+8.9%); instruments $200.2M (+51.8%); Vet software/imaging $345.9M (+10.6%)
“CAG Diagnostics recurring revenue:$3,407,199 $3,129,492 $277,707 8.9%”
New IDEXX inVue Dx Analyzer drove instrument revenue
Instrument revenue +51.8% primarily from new IDEXX inVue Dx Analyzer placements
“The increase in instrument revenue was primarily due to placements of our new IDEXX inVue Dx Analyzer”
Connected IoT and cloud-based product portfolio
Cloud-based veterinary practice management systems, customer communication tools, and connected IoT devices (IDEXX VetLab Stations and analyzers)
“our connected IoT devices (e.g., IDEXX VetLab Stations and analyzers) that enable our integrated, comprehensive diagnostic solution for veterinary practices”
US vs international revenue mix
FY2025 US $2,752.8M; International $1,550.9M (+13.7%)
“United States2,752,785 2,533,174 219,611 8.7%”
FY2025 revenue by segment and geography
FY2025 total revenue $4,303,702K (+10.4% reported, +9.6% organic); CAG $3,953,285K; Water $201,149K; LPD $131,787K
“Total Company$4,303,702 $3,897,504 $406,198 10.4%0.8%— 9.6%”
USD-manufactured product sold internationally
~23% of 2025 revenue (22% 2024, 21% 2023) from USD-manufactured products sold internationally in local currencies
“For the year ended December 31, 2025, approximately 23% of our consolidated revenue was derived from products manufactured or sourced in U.S. dollars and sold internationally in local currencies, compared to 22% and 21% for the years ended December 31, 2024 and 2023, respectively.”
Hedged currency list
Hedges 75%-85% of intercompany product purchase/sale exposure in euro, British pound, Canadian dollar, Japanese yen, Australian dollar; notional $397.6M (2025) vs $325.7M (2024)
“We target to hedge approximately 75% to 85% of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, and Australian dollar.”
FX sensitivity
A 1% strengthening of the U.S. dollar would reduce revenue by ~$16 million and operating income by ~$5 million, net of hedges
“a 1% strengthening of the U.S. dollar would reduce revenue by approximately $16 million and operating income by approximately $5 million, net of hedge positions.”
FX impact on FY2025 results
FX increased FY2025 total revenue growth by 0.8%; FX gains/losses centrally managed
“The impact from changes in foreign currency exchange rates increased total revenue growth by 0.8%.”
Global workforce size and gender mix
~11,000 regular full-time and part-time employees in ~34 countries as of December 31, 2025; 41% men, 59% women
“As of December 31, 2025, we had approximately 11,000 regular full-time and part-time employees in approximately 34 countries around the world”
Volume growth drivers
Volume growth from new business gains, expanded test menu, higher utilization
“Volume growth was supported by new business gains, our expanded menu of available tests, and higher utilization in our loyal customer base”
Supply chain cost exposure to inflation, tariffs, and duties
Cost of goods may be adversely impacted by inflation (including wage inflation), supply restrictions, tariffs or duties, and regulatory requirements
“unanticipated price increases due to factors such as inflation (including wage inflation), supply restrictions beyond our control or the control of our suppliers, the imposition of tariffs or duties”
Inflationary product and labor costs
Gross margin partly offset by inflationary product and labor costs
“which offset the impacts from higher product and labor costs due to, in part, inflationary cost effects”
Debt covenant and interest rate risk
Variable-rate (SOFR-based) Credit Facility with financial covenants; senior notes carry prepayment penalty on early repayment
“Borrowings under our Credit Facility bear interest at variable rates, including rates based on the Secured Overnight Financing Rate (“SOFR”), exposing us to interest rate risk.”
2026 FX impact outlook
2026 FX tailwind expected: +$28M revenue, +$22M operating profit, +$0.22 diluted EPS; assumes EUR $1.16, GBP $1.33, CAD $0.72, AUD $0.66, JPY ¥157
“we anticipate year-over-year changes will increase our revenues, operating profit, and diluted earnings per share in the year ending December 31, 2026, by approximately $28 million, $22 million, and $0.22 per share, respectively.”
Macro and sector headwinds constrain growth
Volume growth partially constrained by macroeconomic and sector headwinds
“partially constrained by macroeconomic and sector headwinds”
2025 stock price range
2025 stock price range: $361.04 low to $766.68 high
“in spite of our operating performance as demonstrated during 2025 where the range of our stock price was from a low of $361.04 to a high of $766.68.”
EPA-approved water testing products
Tecta, Colilert, Colilert-18, Colisure, Quanti-Tray, Filta-Max xpress, Enterolert, SimPlate approved by the EPA for various regulatory programs
“Our Tecta Systems with the Tectalert EC/TC medium, Colilert, Colilert-18, Colisure, Quanti-Tray, Filta-Max xpress, Enterolert, and SimPlate for heterotrophic plate counts products have been approved by the EPA”
Dairy testing FDA/NCIMS regulation with two FDA-validated products
Dairy products in NCIMS milk-monitoring programs are FDA-regulated; IDEXX has two FDA-validated test products, SNAP NBL and SNAP Tetra, for sale in the U.S.
“IDEXX has two FDA-validated test products, SNAP NBL and SNAP Tetra, for sale in the U.S.”
Human point-of-care electrolyte and blood gas analyzers regulated as FDA Class I/II medical devices
Human point-of-care electrolyte and blood gas analyzers are FDA Class I/II medical devices subject to cGMP
“Our human point-of-care electrolyte and blood gas analyzers are classified by the FDA as Class I and/or Class II medical devices”
Broad chemical/environmental product regulations (RoHS, REACH, EMC, Biocidal Products Regulation)
IDEXX products must comply with global regulations including EU RoHS, EMC, REACH, and Biocidal Products Regulation; similar regimes in Australia, China, Turkey, Korea
“All IDEXX products must comply with applicable global product regulations, including those governing consumer product safety and materials requirements such as the Europeans Union's Electromagnetic Compatibility (“EMC”) Directive”
AI and data privacy regulations
Products using AI may be subject to new regulations including the EU Artificial Intelligence Act enacted in August 2024; also subject to GDPR, EU Data Act, FCPA, UK Bribery Act
“including the European Union’s Artificial Intelligence Act enacted in August 2024”
PFAS regulatory attention
PFAS in certain IDEXX products face increasing regulation; Minnesota will ban PFAS in products impacting water products beginning in 2032
“Minnesota will implement a regulation banning PFAS in products that impact water products beginning in 2032”
Third-party supplier dependency including sole/single sources
Relies on third-party suppliers including sole/single sources such as Ortho; proprietary products cannot be readily replaced; mitigations include escrow and safety stock
“we currently purchase many products, components, and materials from sole or single sources, such as Ortho”
Biologic product manufacturing complexity
Many rapid assay, livestock/poultry, water, and dairy products are biologics with inherently variable biological materials; manufacturing failures could force recalls
“Many of our rapid assay, livestock and poultry diagnostic, water, and dairy products are biologic products that include biological materials, such as antibodies, cells, and sera”
Distributor dependence risk
Reliance on distributors who may promote competitors' products; loss of key distributors could reduce revenue
“We may rely on one or more key distributors for a product or a region, and the loss of these distributors could reduce our revenue.”
AI use in products and operations creates risk
IDEXX builds AI into many product and service offerings and internal operations; flawed algorithms, insufficient or infringing datasets could cause reputational harm or liability
“We have built, and expect to continue to build, AI into many of our product and service offerings, and we expect this element of our business to grow”
Key personnel and CEO transition risk
Planned CEO transition in May 2026 announced January 13, 2026; dependence on key personnel
“such as our planned CEO transition in May 2026 that we announced on January 13, 2026”
Cybersecurity and IT systems risk
Dependence on IT systems, cloud providers, and connected IoT devices; past cyberattacks experienced; AI-enhanced threats growing
“the use of AI and other emerging technologies by threat actors is growing, enabling more sophisticated and effective cybersecurity attacks and phishing and social engineering schemes and further increasing attack volume and frequency.”
Cloud-based software delivery dependency
Relies on third-party suppliers to provide cloud-based infrastructure for cloud-based software solutions; disruptions could substantially decrease sales and reduce recurring revenues
“provide the cloud-based infrastructure through which we deliver our cloud-based software solutions”
Operations/supply chain disruption risk
External events (disasters, pandemics, tariffs, raw material unavailability) could disrupt operations, supply chain, and logistics network
“the imposition of regulations, trade protection measures, tariffs, duties, import/export restrictions, quotas or embargoes on key components; transportation failures affecting the supply and shipment of materials and finished goods; and the unavailability of raw materials.”
Macroeconomic and inflation risk
Macroeconomic conditions, inflation, wages, and interest rates may raise costs and reduce veterinary diagnostic demand
“For our veterinary customers, these events may negatively affect the number of patient visits and elective procedures, and the volume of diagnostic utilization, which could adversely affect our revenues.”
CAG segment ($3.95B of $4.30B revenue) is driven by companion animal healthcare testing volumes and prices.
“growth in CAG Diagnostics recurring revenue, including benefits from higher volumes and higher realized prices”
Largest recurring product line at $1,496.8M, +14.8%, driven by installed base growth and expanded test menu.
“IDEXX VetLab consumables1,496,752 1,303,250 193,502 14.8%”
New analyzer placements drove 51.8% reported growth in CAG Diagnostics capital - instruments revenue.
“primarily due to placements of our new IDEXX inVue Dx Analyzer”
Ortho is a sole or single-source supplier; its products are proprietary and cannot be readily replaced, used in instruments, consumables and accessories; livestock and poultry diagnostic tests, dairy testing products; and water testing products.
“we currently purchase many products, components, and materials from sole or single sources, such as Ortho”
Higher utilization in loyal customer base and high retention rates support consumable and testing volume growth.
“higher utilization in our loyal customer base, partially constrained by macroeconomic and sector headwinds”
Installed base growth of point-of-care analyzers drives recurring consumables, services, and accessories demand, a core revenue mechanism.
“grow our installed base of instruments, and increase demand for related recurring sales of consumable products, services, and accessories”
$1,424.1M revenue, +6.6%, driven by higher testing volumes in North America, Europe, and Asia Pacific.
“higher testing volumes in North America, Europe, and Asia Pacific and higher realized prices”
Biologic products depend on antibodies, cells, and sera; sourcing and manufacturing variability can prevent supply and force recalls.
“Many of our rapid assay, livestock and poultry diagnostic, water, and dairy products are biologic products that include biological materials, such as antibodies, cells, and sera”
International revenue of $1,550.9M (36% of total) exposes results to FX; FX added 0.8% to revenue growth; transaction gains/losses centrally managed.
“International1,550,917 1,364,330 186,587 13.7%2.3%— 11.3%”
IDEXX depends on distributors to promote and create demand; loss of key distributors or changes in their inventory levels could reduce revenue growth.
“we are dependent on these distributors to promote and create demand for our products”
Cloud-based software solutions depend on third-party cloud infrastructure; disruptions could decrease sales and recurring revenues.
“provide the cloud-based infrastructure through which we deliver our cloud-based software solutions”
Imposition of tariffs or duties and inflation including wage inflation can raise supply chain costs and cost of goods.
“the imposition of tariffs or duties, or regulatory requirements regarding the importation, exportation, composition, or production processes of the goods or materials provided by our suppliers”
Certain IDEXX products may contain PFAS, subject to increasing EU, EPA, and state regulation including a Minnesota ban starting 2032; compliance may require product reformulation.
“PFAS (per- and polyfluoroalkyl substances), which may be contained in certain IDEXX products, are a subject of increasing regulatory attention”
Euro is one of the primary hedged currencies for intercompany purchases/sales; 2026 outlook assumes euro at $1.16.
“We primarily hedge intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, and Australian dollar.”
Inflationary product and labor costs offset pricing and productivity benefits in gross margin.
“offset the impacts from higher product and labor costs due to, in part, inflationary cost effects”
Customer shift of pancreatic lipase testing to Catalyst platform decreased rapid assay revenue (-3.0%).
“a shift of customers' pancreatic lipase testing to our Catalyst instrument platform”
Macroeconomic conditions affecting consumer spending influence veterinary patient visits, elective procedures, and diagnostic utilization volumes.
“For our veterinary customers, these events may negatively affect the number of patient visits and elective procedures, and the volume of diagnostic utilization”
Cloud-based products and IoT-connected diagnostic devices rely on third-party cloud providers; disruption or breach could impair product delivery.
“these products and services rely on third-party providers for cloud computing and storage”
IDEXX products incorporating AI may be subject to emerging regulations including the EU AI Act enacted August 2024.
“Our products that use generative or other forms of artificial intelligence (“AI”) may also be subject to new and emerging law and regulations, including the European Union’s Artificial Intelligence Act enacted in August 2024”
Inflationary pressures, wage increases, and rising interest rates are disclosed as factors that could increase costs and disrupt operations.
“inflationary pressures, which may increase costs for materials and finished goods”
Variable-rate SOFR-based Credit Facility borrowings expose IDEXX to rising interest rates increasing debt service obligations.
“If interest rates were to increase, our debt service obligations under our variable-rate Credit Facility would increase even if the principal amount borrowed remained the same.”
Tariffs, duties, import/export restrictions, quotas, and embargoes on key components are disclosed as potential disruptions to supply chain and logistics.
“the imposition of regulations, trade protection measures, tariffs, duties, import/export restrictions, quotas or embargoes on key components”
See which prediction-market events move IDXX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Zacks Investment Research • STOCK • 11/06/2026, 12:52:04
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Zacks Investment Research • STOCK • 09/06/2026, 12:46:12
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
MarketBeat • STOCK • 30/05/2026, 09:02:41
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Seeking Alpha • STOCK • 27/05/2026, 15:27:05
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
Business Wire • STOCK • 14/05/2026, 18:34:00
IDEXX Laboratories (NASDAQ: IDXX) Reports Strong Quarterly Results, Exceeding Expectations
Market Data • Market Data • 05/05/2026, 21:01:12
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 05/05/2026, 16:11:13
IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up
Zacks Investment Research • STOCK • 05/05/2026, 13:31:21
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research • STOCK • 05/05/2026, 10:45:30
IDEXX Laboratories Announces First Quarter Results
Business Wire • STOCK • 05/05/2026, 08:30:00
Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings
Zacks Investment Research • STOCK • 01/05/2026, 12:11:20
IDEXX Laboratories (NASDAQ: IDXX) Stock Analysis: Neutral Rating Amid Valuation Concerns and Growth Drivers
Market Data • Market Data • 28/04/2026, 16:11:01